Wegovy HD goes on sale nationwide at $399 a month self-pay

Novo Nordisk said on April 7, 2026 that Wegovy HD (semaglutide) injection 7.2 mg is available nationwide, roughly three weeks after the FDA cleared it ^[1][2]. Self-paying adults prescribed the higher dose can expect to pay $399 per month, while commercially insured patients may pay as little as $25 per month through the Wegovy savings offer ^[1][2].

The company said the dose is stocked at more than 70,000 US pharmacies and is also available through NovoCare Pharmacy, select telehealth providers "and more" ^[1][2]. Before this launch, the highest approved Wegovy injection dose for weight loss was 2.4 mg ^[1][2]. Reuters reported the 7.2 mg version was approved last month under the FDA Commissioner's National Priority Review Voucher program ^[2]. Novo said Wegovy HD is assembled and packaged at its Clayton, North Carolina facility ^[1].

How the pricing works

The $399 price sits $50 above the $349 monthly self-pay price Novo lists for Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg ^[1]. Patients new to the Wegovy savings offer or NovoCare Pharmacy pay $199 for each month of the 0.25 mg and 0.5 mg starting doses, for two monthly fills through June 30, 2026, before the standard prices apply ^[1]. Novo defines one month as one box of four pens ^[1].

The $25 commercial-insurance offer is capped at $100 in savings per month and excludes government beneficiaries, such as people on Medicare or Medicaid ^[1]. Novo says it can change or cancel either program at any time ^[1]. Separately, Reuters reported in March that Novo plans to launch a discounted subscription plan for US self-pay Wegovy patients, aimed at winning back ground lost to Eli Lilly in the obesity-drug market ^[2]. Details and timing of that subscription plan are not in these sources.

What the trial showed

Approval was based on the phase 3 STEP UP trial, a 72-week randomized, double-blind study in 1,407 adults with a BMI of 30 or higher and without diabetes, comparing semaglutide 7.2 mg against semaglutide 2.4 mg and placebo alongside lifestyle changes ^[1].

In the analysis assuming everyone stayed on treatment, average weight reduction was about 21% (20.7%) with 7.2 mg, about 18% (17.5%) with 2.4 mg, and about 2% (2.4%) with placebo ^[1]. In the analysis counting all patients regardless of whether they stayed on treatment, the figures were about 19% (18.8%), about 16% (15.5%) and about 4% (3.9%) ^[1]. Baseline body weight averaged 248 pounds in the 7.2 mg and placebo groups and 257 pounds in the 2.4 mg group ^[1].

About 31.2% of people on 7.2 mg lost 25% or more of their body weight, versus 15.3% on 2.4 mg and 0% on placebo ^[1]. And 89% on Wegovy HD lost at least 5% of body weight, compared with 38% on placebo ^[1].

Common adverse reactions included nausea, vomiting, dysesthesia, constipation, abdominal pain, fatigue, headache, dizziness, hair loss and flatulence ^[1]. Permanent discontinuation due to adverse reactions was similar between doses: 5% on Wegovy HD, 5% on 2.4 mg and 2% on placebo ^[1]. One difference stood out: events involving altered skin sensation, such as sensitive skin, hyperesthesia, dysesthesia and paresthesia, were reported by 22% of the Wegovy HD group, versus 6% on 2.4 mg and 0.3% on placebo ^[1].

Why it matters for patients

For people paying cash, the practical change is a new tier. Staying at 2.4 mg costs $349 a month under Novo's self-pay program; moving to 7.2 mg costs $399, a difference of $600 a year ^[1]. The trial data suggest the higher dose delivers a few more percentage points of average weight loss, and roughly double the share of people reaching 25% or more loss, but also a notably higher rate of skin-sensation side effects ^[1].

Insurance coverage for the new dose is not addressed in these sources, and it is not yet known how commercial plans or pharmacy benefit managers will treat 7.2 mg compared with lower doses. Also note that the cardiovascular risk-reduction indication described in Novo's announcement refers to the 2.4 mg dose in adults with known heart disease ^[1].

What happens next

The $199 introductory pricing on the 0.25 mg and 0.5 mg starting doses runs through June 30, 2026, after which Novo's listed self-pay prices of $349 and $399 apply ^[1]. Novo's planned self-pay subscription plan had not launched as of these reports ^[2].